

CME INSTITUTE

collective mindfulness

#Tweetorial: Reviewing LAI vs. Oral Data in the Treatment of Schizophrenia

April 25, 2023

[VIEW ON TWITTER](#)

Accreditation Statement

The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Faculty Affiliations

John Lauriello, MD

Professor and Chair of Psychiatry and Human Behavior
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, Pennsylvania

Leslie Citrome, MD, MPH

Clinical Professor of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York


Amber R Hoberg, PMHNP-BC

Psychiatric Nurse Practitioner
Morning Star Family Medicine
San Antonio, Texas

Financial Disclosure

The CME Institute adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME). Any individuals in a position to control the content of a continuing education activity, including faculty, content developers, reviewers, staff, and others, are required to disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The CME Institute has mitigated all relevant conflicts of interest prior to the commencement of the activity. None of the individuals involved in the content have relevant financial relationships with ineligible companies except the following:



CME INSTITUTE

collective mindfulness

Ms. Hoberg is a consultant for Teva, Neurocrine. Has received speaker honoraria from Teva, Neurocrine, Intracellular Therapies, Avanir, Acadia, Axsome, and BioXcel. She has also received advisory board fees from Teva, Acadia, Intracellular Therapies, Sunovion and Neurocrine.

Dr. Lauriello is a consultant for Karuna Pharmaceuticals, Avanir Therapeutics, Teva and BioXcel .

Dr. Citrome is a consultant for AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Cerevel, Clinilabs, COMPASS, Eisai, Enteris BioPharma, HLS Therapeutics, Idorsia, INmune Bio, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Lyndra, Medavante-ProPhase, Marvin, Merck, Mitsubishi-Tanabe Pharma, Neurocrine, Neurelis, Novartis, Noven, Otsuka, Ovid, Praxis, Recordati, Relmada, Reviva, Sage, Sunovion, Supernus, Teva. He is a stockshare holder for Bristol-Myers Squibb, Eli Lilly, J & J, Merck and has stock options for Reviva. He has received speaker honoraria from AbbVie/Allergan, Acadia, Alkermes, Angelini, Axsome, BioXcel, Eisai, Idorsia, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Recordati, Sage, Sunovion, Takeda, and Teva. He has received publishing/royalty income from Royalties/Publishing Income: Taylor & Francis, Wiley, International Journal of Clinical Practice, UpToDate , Springer Healthcare, Elsevier.

None of the other planners, reviewers, and CME Institute staff for this educational activity have relevant financial relationships with ineligible companies to disclose. All relevant financial relationships have been mitigated.

Tweetorial References

Tweet #6

Jauhar S, Johnstone M, McKenna PJ. Schizophrenia. Lancet. 2022 Jan 29;399(10323):473-486. doi: 10.1016/S0140-6736(21)01730-X

Tweet #7


Heres S, Lambert M, Vauth R. Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics. Eur Psychiatry. 2014 Nov;29 Suppl 2:1409-13. doi: 10.1016/S0924-9338(14)70001-X. Epub 2014 Nov 22

Tweet #9

Wong KO, Klarenbach SW, Martins KJB, et al. Health resource utilization and cost before versus after initiation of second-generation long-acting injectable antipsychotics among adults with schizophrenia in Alberta, Canada: a retrospective, observational single-arm study. BMC Psychiatry. 2022 Jul 2;22(1):444. doi: 10.1186/s12888-022-04075-y

Tweet #11

American Psychiatric Association. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. Published online August 31, 2020. doi: <https://doi.org/10.1176/appi.books.9780890424841>



CME INSTITUTE

collective mindfulness

2019-2020 Florida Best Practice Psychotherapeutic Medication Guidelines for Adults.

https://floridabhcenter.org/wp-content/uploads/2021/04/2019-Psychotherapeutic-Medication-Guidelines-for-Adults-with-References_06-04-20.pdf

Tweet #13

Kane JM, Schooler NR, Marcy P, et al. Patients With Early-Phase Schizophrenia Will Accept Treatment With Sustained-Release Medication (Long-Acting Injectable Antipsychotics): Results From the Recruitment Phase of the PRELAPSE Trial. *J Clin Psychiatry*. 2019 Apr 23;80(3):18m12546. doi: 10.4088/JCP.18m12546

Tweet #14

Herz MI, Glazer WM, Mostert MA, et al. Intermittent vs maintenance medication in schizophrenia. Two-year results. *Arch Gen Psychiatry*. 1991 Apr;48(4):333-9. doi: 10.1001/archpsyc.1991.01810280049007

Tweet #16

Kane JM, Schooler NR, Marcy P, et al. Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial. *JAMA Psychiatry*. 2020 Dec 1;77(12):1217-1224. doi: 10.1001/jamapsychiatry.2020.2076. Erratum in: *JAMA Psychiatry*. 2020 Dec 1;77(12):1310

Tweet #17

Kane JM, Schooler NR, Marcy P, et al. Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial. *JAMA Psychiatry*. 2020 Dec 1;77(12):1217-1224. doi: 10.1001/jamapsychiatry.2020.2076. Erratum in: *JAMA Psychiatry*. 2020 Dec 1;77(12):1310

Tweet #19

Sajatovic M, Ross R, Legacy SN, et al. Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics - expert consensus survey part 1. *Neuropsychiatr Dis Treat*. 2018;14:1463-1474.

Heres S, Hamann J, Kissling W, Leucht S. Attitudes of psychiatrists toward antipsychotic depot medication. *J Clin Psychiatry*. 2006 Dec;67(12):1948-53. doi: 10.4088/jcp.v67n1216.

Jaeger M, Rossler W. Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists. *Psychiatry Res*. 2010 Jan 30;175(1-2):58-62. doi: 10.1016/j.psychres.2008.11.003. Epub 2009 Dec 11.

Tweet #20

Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. *Am J Psychiatry*. 2011 Jun;168(6):603-9. doi: 10.1176/appi.ajp.2011.10081224. Epub 2011 Mar 1. Erratum in: *Am J Psychiatry*. 2012 Feb;169(2):223

Tweet #21

Buckley PF, Schooler NR, Goff DC, et al; PROACTIVE Study. Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. *Schizophr Bull*. 2015 Mar;41(2):449-59. doi: 10.1093/schbul/sbu067. Epub 2014 May 27



CME INSTITUTE

collective mindfulness

Tweet #22

Alphs L, Benson C, Cheshire-Kinney K, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. *J Clin Psychiatry*. 2015 May;76(5):554-61. doi: 10.4088/JCP.14m09584

Tweet #23

Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. *Lancet Psychiatry*. 2021;8(5):387-404.



CME INSTITUTE
collective mindfulness

GLOSSARY

AA Antipsychotic Agent

APA American Psychiatric Association

CC Clinician's Choice

LAI Long-Acting Injectable

LAI AA Long-Acting Injectable Antipsychotic Agent

LAIA Long-Acting Injectable Antipsychotic

OA Oral Antipsychotic

OA AA Orally-Administered Antipsychotic Agent

SGA Second-Generation Antipsychotic